AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-8 (Canceled)

9. (Previously presented): A method of treating an allergic disease in a mammal, comprising administering an effective amount of a compound represented by formula (I) or a salt or a solvate thereof:



(I)

wherein R represents an oxo group or a halogen atom, R^{1-1} and R^{1-2} each independently represent a C1-4 alkyl group, and R^{1-3} represents a C1-10 alkyl group, a C2-10 alkenylene group, or a C2-10 alkynylene group substituted by a C1-10 alkyl group, a C2-10 alkenylene group, a C2-10 alkynylene group, a phenyl group, a phenoxy group, a C3-7 cycloalkyl group, or a C3-7 cycloalkyloxy group, wherein the phenyl and cycloalkyl groups may be substituted by 1-3 of C1-4 alkyl groups, C1-4 alkoxy groups, halogen atoms, trihalomethyl groups, or nitro groups, to a mammal having an allergic disease, thereby treating an allergic disease in a mammal.

Claim 10 (Canceled)

11. (Previously presented): The method of treating an allergic disease according to claim 9, wherein said allergic disease is selected from the group consisting of an allergic

respiratory disease, an allergic nasal disease, an allergic skin disease, and an allergic ocular disease.

12. (Previously presented): The method of treating an allergic disease according to claim 11, wherein said allergic respiratory disease is selected from the group consisting of bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, the allergic nasal disease is allergic rhinitis, vernal catarrh, hay fever, or chronic allergic rhinitis, the allergic skin disease is atopic dermatitis, or the allergic ocular disease is seasonal allergic conjunctivitis, hay fever, and chronic allergic conjunctivitis.

13. (Previously presented): The method of treating an allergic disease according to claim 11, wherein said allergic respiratory disease is selected from the group consisting of bronchial asthma, pediatric asthma, allergic asthma, and atopic asthma.

Claim 14 (Canceled)

15. (Previously presented): The method of treating an allergic disease according to claim 9, wherein said compound represented by the formula (I) is 11α,15α-dimethoxy-9-oxoprosta-5Z,13E-dienoic acid or a salt or a solvate thereof.

Claim 16. (Canceled)

17. (Currently amended): The method of treating an allergic disease according to claim 9, further comprising administration of one or more drugs selected from the group consisting of anti-asthma drugs, inhaled steroid drugs, inhaled β2 stimulants, methylxanthine asthma drugs, anti-allergy drugs, histamine H1-antagonists, ~~antiinflammatory~~ anti-inflammatory drugs, anti-choline drugs, thromboxane antagonists, leukotriene antagonists, LTD4 antagonists, PAF

antagonists, phosphodiesterase inhibitors, β2 agonist, steroid drugs, mediator release-suppressing drugs, eosinophil chemotactic-suppressing drugs, disodium cromoglycate, macrolide antibiotics, immune-suppressing agent, and hyposensitization therapy agents, before, after or in combination with an effective amount of the compound represented by formula (I).

18. (New): A method of treating an allergic disease in a mammal, comprising orally administering a compound represented by formula (I) or a salt or a solvate thereof in an amount of 1 μg to 100 mg per dose one or more times a day, or parenterally administering the compound represented by Formula (I) or a salt or a solvate thereof in an amount of 0.1 ng to 10 mg per dose one or more times a day:



(I)

wherein R represents an oxo group or a halogen atom, R^{1-1} and R^{1-2} each independently represent a C1-4 alkyl group, and R^{1-3} represents a C1-10 alkyl group, a C2-10 alkenylene group, or a C2-10 alkynylene group substituted by a C1-10 alkyl group, a C2-10 alkenylene group, a C2-10 alkynylene group, a phenyl group, a phenoxy group, a C3-7 cycloalkyl group, or a C3-7 cycloalkyloxy group, wherein the phenyl and cycloalkyl groups may be substituted by 1-3 of C1-4 alkyl groups, C1-4 alkoxy groups, halogen atoms, trihalomethyl groups, or nitro groups, to a mammal having an allergic disease, thereby treating an allergic disease in a mammal.

19. (New): The method of treating an allergic disease according to claim 18, wherein said parenteral administration comprises intravenously administering the compound represented by Formula (I) or a salt or a solvate thereof.